February 2025 The FDA issued additional warnings about the risks of gastroparesis associated with GLP-1 receptor agonists, emphasizing the need for comprehensive patient education about potential complications [1]
Ten units falls into the lower-to-moderate range of typical dosing protocols, which begin at doses as low as 0.25 mg (approximately 2.5 units) and progress upward based on tolerance and clinical response
Tirzepatide trials showed nausea in 2633% of participants compared to 37% in semaglutide trials, but individual genetics and dose-escalation speed matter more than medication choice alone
Not knowing exactly what causes NAION makes it even more difficult to understand the drugs role in developing the condition
This is in line with Phase II study results for semaglutide treatment in participants with type 2 diabetes, with 11% of total participants withdrawing from the trial due to AEs (vs 12.9% in the present study), primarily due to GI AEs in the first month of treatment [16]
GLP-1 medications offer none of these benefitsin fact, they often undermine them
